Floatz logo

Relebactam

Cystic Fibrosis

Hartford HospitalSmall moleculePhase 4 / ApprovedActive
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

80 Active assets in the Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
Elexacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

Relebactam is also rated in:

bacterial pneumoniaActive
CCC
Indicative · Phase 4
53 / 100
View asset →
hematopoietic and lymphoid cell neoplasmActive
CCC
Indicative · Phase 2
48 / 100
View asset →
cancerActive
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →